Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877488 | 1.00 | LMNA (0.43) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL3872846 | 1.00 | LMNA (0.43) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4641281 | 1.00 | LMNA (0.43) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2227845 | 0.90 | — | — | |
| SCHEMBL23413533 | 0.90 | — | — | |
| SCHEMBL19439531 | 0.87 | LCK (0.37) | LMNALCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL8032127 | 0.83 | LMNA (0.62) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2344301 | 0.83 | LMNA (0.55) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2398065 | 0.83 | LMNA (0.48) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL9672577 | 0.83 | LMNA (0.48) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491745-B2 | Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2007-02-15 | — | — | US | disclosed |
| EP-1431286-A2 | Prodigiosin derivatives for treating cancer or viral diseases | Gemin X Biotechnologies Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X BIOTECHNOLOGIES INC. | 2004-01-22 | — | — | US | disclosed |
| US-6602879-B2 | For inhibiting the replication or infectivity of a virus; therapy | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-08-05 | — | — | US | disclosed |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2003-01-09 | — | — | US | disclosed |
| EP-1255753-A2 | PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS | Gemin X Biotechnologies Inc. (CA) | 2002-11-13 | — | — | EP | disclosed |
| US-6407244-B1 | ANTIPROLIFERATIVE AGENT | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2002-06-18 | — | — | US | disclosed |
| WO-2001055131-A2 | PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | LMNA 3539/4885ALDH1A1 3326/4885HSD17B10 3459/4885 |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | LMNA 3539/4885ALDH1A1 3326/4885HSD17B10 3459/4885 |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | POLI, PCNA, ELL | LMNA 2969/4885ALDH1A1 2915/4885HSD17B10 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.